Skip to main content
Indian Journal of Pharmacology logoLink to Indian Journal of Pharmacology
letter
. 2020 Oct 14;52(4):339–340. doi: 10.4103/ijp.IJP_691_20

Chlorpromazine-induced lenticular opacity

Kavitha Srinivasan 1,, Megha Gopalakrishna 1
PMCID: PMC7722913  PMID: 33078739

Sir,

A 50-year-old female presented with occasional glare for 2 years. She had a history of taking chlorpromazine (CPZ) tablet 400 mg daily for schizophrenia for more than 10 years. Her vision was 6/9 in both eyes. On examination, she had bilateral stellate, brownish, granular deposits along the suture lines on the anterior surface of the lens, in the visual axis [Figure 1]. This was seen more prominently on retro-illumination [Figure 2]. The cornea was clear.

Figure 1.

Figure 1

Slit-lamp examination showing chlorpromazine-induced star-shaped anterior lenticular opacity

Figure 2.

Figure 2

The retro-illumination mode enhancing the star shape of the opacity caused by chlorpromazine

CPZ is an established drug for psychiatric diseases, especially schizophrenia. Among the ocular adverse effects of CPZ, corneal pigmentary changes and various stages of lenticular opacities are common.[1] The lenticular changes are dose related and categorized into five grades.[2] They range from fine dot-like opacities, stellate cataract, to solidly opaque mass. Despite being such significant opacities, they usually do not compromise on visual acuity until advanced stage.[3] However, patients usually complain of glare and halos. Stopping the drug has not shown to reverse the condition usually, but the progression can be arrested. Psychiatrists prescribing these medications must be well aware of this adverse effect and refer the patient to an ophthalmologist in case of development of symptoms and plan on changing the medication. Our patient had bilateral Grade 4 lens deposits without any corneal deposit secondary to CPZ. Ophthalmologists must also be aware of this possibility so that reassurance can be given to patients.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  • 1.Subashini K, Rao V A. Chlorpromazine-induced cataract and corneal pigmentation. Indian J Pharmacol. 2004;36:323–4. [Google Scholar]
  • 2.Thaler JS, Curinga R, Kiracofe G. Relation of graded ocular anterior chamber pigmentation to phenothiazine intake in schizophrenics-quantification procedures. Am J Optom Physiol Opt. 1985;62:600–4. doi: 10.1097/00006324-198509000-00004. [DOI] [PubMed] [Google Scholar]
  • 3.Ooi IL, Umi Kalthum MN, Suzaily W, Aida Zairani MZ, Yong TK. Ocular manifestation of chlorpromazine toxicity: A case report. J Ophthalmic Pathol. 2014;3:2. [Google Scholar]

Articles from Indian Journal of Pharmacology are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES